Overview

Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of previous treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
Consortium for Improving Survival of Lymphoma
Treatments:
BB 1101
Bortezomib
Cytarabine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate